睿知中国医院研究地图
候选清单

广州

广东省中医院

Guangdong Provincial Hospital of Chinese Medicine

在本站收录的 61 种疾病中,这家医院列在其中 22 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

广东省中医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma5 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma25 篇牵头论文
  3. 胃癌Stomach cancer12 篇牵头论文
  4. 肺癌Lung cancer41 篇牵头论文
  5. 胰腺癌Pancreatic cancer6 篇牵头论文
  6. 乳腺癌Breast cancer50 篇牵头论文牵头 1 项开放试验
  7. 胶质瘤Glioma12 篇牵头论文
  8. 骨肉瘤Osteosarcoma2 篇牵头论文
  9. 胃肠道间质瘤Gastrointestinal stromal tumour1 篇牵头论文
  10. 神经母细胞瘤Neuroblastoma3 篇牵头论文
  11. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  12. β 地中海贫血Beta thalassaemia0 篇牵头论文
  13. 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder4 篇牵头论文
  14. 重症肌无力Myasthenia gravis0 篇牵头论文
  15. 冠心病Coronary heart disease15 篇牵头论文
  16. 先天性心脏病Congenital heart disease7 篇牵头论文
  17. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  18. 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
  19. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
  20. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis4 篇牵头论文
  21. IgA 肾病IgA nephropathy6 篇牵头论文
  22. 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、肝母细胞瘤、视网膜母细胞瘤、脊索瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、淋巴瘤、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、烟雾病、肝豆状核变性、胆道闭锁、脊柱侧弯、大动脉炎、肝包虫病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.2%。

牵头论文
5
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 332025

广州有 24 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。

这些数字背后的记录
研究主题影像与人工智能
论文中的科室放疗科神经外科耳鼻喉/头颈外科
牵头的论文5
  1. Clinical Study of Tuhuanglian Liquid Wet Compress on Acute Radiation Dermatitis of Nasopharyngeal Carcinoma.2025Critical reviews in biomedical engineeringRCT
  2. Therapeutic association and mechanistic exploration of modified Sijunzi Decoction in radiation-induced sinusitis: an integrated retrospective analysis and network pharmacology study.2025European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  3. Efficient T staging in nasopharyngeal carcinoma via deep Learning-Based Multi-Modal classification.2025European journal of radiology
  4. Survival analysis of a comprehensive treatment strategy for internal carotid artery blowout syndrome by nasopharyngeal carcinoma.2023Head & neck
  5. Prognostic generalization of multi-level CT-dose fusion dosiomics from primary tumor and lymph node in nasopharyngeal carcinoma.2023Medical physics
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens状态不明NCT01762514研究中心II期2013-01 启动
PubMed 以外找到的论文(未计入)4
  1. ASO Visual Abstract: Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma2025Annals of Surgical Oncology论文
  2. Additional file 3 of FLI1 regulates radiotherapy resistance in nasopharyngeal carcinoma through TIE1-mediated PI3K/AKT signaling pathway2023Figshare数据集
  3. PD-1 Combined with VEGF/VEGFR2 Inhibitors for the Re-Treatment of Metastatic Nasopharyngeal Carcinoma2023Journal of Biomedical Nanotechnology论文
  4. Survival Follow-Up Analysis of EBBA Treatment Strategy for Internal Carotid Artery Invasion by Nasopharyngeal Carcinoma2022SSRN Electronic Journal预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.2%。

牵头论文
25
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 2220222023: 3320232024: 111120242025: 552025

广州有 15 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    分期
    未注明
    开始
    2025-09
    发布
    登记号
    NCT07170345

    年龄 18 岁 至 18 岁(登记的条件)

    牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州

  2. 正在招募
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    分期
    未注明
    开始
    2023-11
    发布
    登记号
    NCT06157060

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:南方医科大学珠江医院;另有 3 家列出的医院为研究中心广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像、人工智能与早期发现局部治疗(消融、TACE、HAIC)免疫与靶向药物
论文中的科室病理/检验科肿瘤内科消化/肝病科

这些论文过半是实验室或动物研究。

牵头的论文25
  1. Triptolide impacts CSF1R expression and reprograms the suppressive function of myeloid-derived suppressor cells via targeting the ER stress pathway.2026Cytokine
  2. Identification and validation of an explainable machine learning model for hepatocellular carcinoma at high risk: a retrospective multicenter cohort study.2026International journal of surgery (London, England)免费全文
  3. Simultaneous versus sequential transcatheter arterial chemoembolization combined with microwave ablation for hepatocellular carcinoma: A retrospective propensity score-matched analysis.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  4. Molecular subtyping and therapeutic prediction of hepatocellular carcinoma based on exosome proteomics.2025International journal of biological macromolecules
  5. Nano-pectic polysaccharide from vinegar-baked Radix Bupleuri enhances methotrexate efficacy against hepatocellular carcinoma via BCRP and MRP2 downregulation.2025International journal of biological macromolecules
  6. The combination of serum lncRNA PTTG3P and mRNA PTTG1 serves as a diagnostic and prognostic marker for hepatocellular carcinoma.2025Molecular medicine reports免费全文
  7. Decoding the possible mechanism of action of Paeoniflorigenone in combating Aflatoxin B1-induced liver cancer: an investigation using network pharmacology and bioinformatics analysis.2025Toxicology mechanisms and methods
  8. Astragalus polysaccharide enhances antitumoral effects of chimeric antigen receptor- engineered (CAR) T cells by increasing CD122+CXCR3+PD-1- memory T cells.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.2024Cancer immunology research
  10. Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.2024European radiology免费全文
  11. Peripheral blood lymphocyte subsets predict the efficacy of TACE with or without PD-1 inhibitors in patients with hepatocellular carcinoma: a prospective clinical study.2024Frontiers in immunology免费全文
  12. Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinoma.2024Frontiers of medicine
  13. Comparison of structure and the synergistic anti-hepatocellular carcinoma effect of three polysaccharides from vinegar-baked Radix Bupleuri.2024International journal of biological macromolecules
  14. Surgical resection versus thermal ablation after intra-arterial conversion therapy for unresectable hepatocellular carcinoma: a multicenter retrospective one as per the STROBE guidelines.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  15. Multiparametric MRI based deep learning model for prediction of early recurrence of hepatocellular carcinoma after SR following TACE.2024Journal of cancer research and clinical oncology免费全文
  16. Rapid evaluation of hepatocellular carcinoma by detecting plasma exosomes with time-resolved fluorescence immunochromatographic test strips.2024Mikrochimica acta
  17. Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.2024Scientific reports免费全文
  18. Tanshinone IIA modulates cancer cell morphology and movement via Rho GTPases-mediated actin cytoskeleton remodeling.2024Toxicology and applied pharmacology
  19. The application of arsenic trioxide in cancer: An umbrella review of meta-analyses based on randomized controlled trials.2023Journal of ethnopharmacology
  20. Human Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation for Patients with Decompensated Liver Cirrhosis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract免费全文
  21. Shentao Ruangan formula promotes apoptosis via the E2F2-p53 pathway in hepatocellular carcinoma.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. Crosstalk of LncRNA HOTAIR and SP1-mediated repression of PDK1 contributes to β-Elemene-inhibited proliferation of hepatocellular carcinoma cells.2022Journal of ethnopharmacology
  23. Solamargine inhibits the growth of hepatocellular carcinoma and enhances the anticancer effect of sorafenib by regulating HOTTIP-TUG1/miR-4726-5p/MUC1 pathway.2022Molecular carcinogenesis免费全文
  24. MIL-1, a novel antitumor agent derived from natural product millepachine, acts as tubulin polymerization inhibitor for the treatment of hepatocellular carcinoma.2021European journal of pharmacology
  25. Identification of metabolism genes related to hepatocarcinogenesis and progression in type 2 diabetes mellitus via co-expression networks analysis.2021Hereditas免费全文
中文论文(未计入)1
  1. [Efficacy and safety of transcatheter arterial chemoembolization followed by hepatic arterial infusion chemotherapy combined with TKI and PD-1 inhibitors as first-line treatment for advanced hepatocellular carcinoma].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion正在招募NCT07170345研究中心2025-09 启动
  2. Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA正在招募NCT06157060研究中心2023-11 启动
  3. YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)已完成NCT04000737研究中心II期2020-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.1%。

牵头论文
12
2021–2025 年
牵头试验
5
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 4420232024: 2220242025: 112025

广州有 15 家医院列在胃癌下全国有 211 家医院列在胃癌下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    发布
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 32 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  2. 即将招募
    Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery
    分期
    不分期
    开始
    2025-08
    发布
    登记号
    NCT07098949

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心广州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术化疗与综合治疗营养与康复
论文中的科室肿瘤内科消化/肝病科影像/核医学科病理/检验科
牵头的论文12
  1. Yiqi Huayu Jiedu formula inhibits JAK2/STAT3-mediated partial EMT in treating chronic atrophic gastritis.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  2. Feasibility and value of modular splenic hilar lymphadenectomy technique in laparoscopic total gastrectomy: a retrospective-controlled research.2024Surgical endoscopy
  3. Transthoracic single-port-assisted laparoscopic gastrectomy versus laparoscopic transhiatal approach for Siewert type II adenocarcinoma of the esophagogastric junction: a single-center retrospective study.2024Surgical endoscopy
  4. Electro-acupuncture for health-related quality of life and symptoms in patients with gastric cancer undergoing adjuvant chemotherapy (EAGER): a protocol for a multicenter randomized controlled trial.2023Health and quality of life outcomes免费全文
  5. Risk factors for surgical site infection in patients with gastric cancer: A meta-analysis.2023International wound journal免费全文
  6. Hand-sewn esophagojejunostomy in transthoracic single-port assisted laparoscopic esophagogastrectomy for Siewert type II adenocarcinoma of the esophagogastric junction with esophageal invasion > 3 cm.2023Surgical endoscopy
  7. Quantitative parameters in novel spectral computed tomography: Assessment of Ki-67 expression in patients with gastric adenocarcinoma.2023World journal of gastroenterology免费全文
  8. Transthoracic Single-Port Assisted Laparoscopic Five-Step Maneuver Lower Mediastinal Lymphadenectomy for Siewert Type II Adenocarcinoma of the Esophagogastric Junction.2022Annals of surgical oncology
  9. Whether the infracardiac bursa protect right pleura during laparoscopic radical operation of Siewert type II adenocarcinoma of esophagogastric junction?2022BMC cancer免费全文
  10. Diet and gastric cancer risk: an umbrella review of systematic reviews and meta-analyses of prospective cohort studies.2022Journal of cancer research and clinical oncology免费全文
  11. Acupuncture for Quality of Life in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy.2022Journal of pain and symptom managementRCT免费全文
  12. Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL‑6/JAK/STAT3‑mediated PD‑L1 activity.2021International journal of molecular medicine免费全文
中文论文(未计入)5
  1. [A retrospective study on an innovative modular surgical technique in laparoscopic total gastrectomy combined with spleen-preserving hilar lymphadenectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Gastric hamartomatous inverted polyps: a clinicopathological analysis of five cases].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [A case report of gastric adenocarcinoma of fundic gland type as suspected gastric neuroendocrine tumor].2022Zhonghua nei ke za zhi
  4. [Safety and feasibility of intrathoracic modified overlap esophagojejunostomy in laparoscopic radical resection of Siewert type Ⅱ adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Safety and feasibility of laparoscopic double-flap technique in digestive tract reconstruction after proximal gastrectomy for esophagogastric junction tumors larger than 5 cm].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)16
  1. FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis状态不明NCT04886193牵头方不分期2021-04 启动
  2. Laparoscopic Total Gastrectomy With Versus Without Bursectomy状态不明NCT03117283牵头方II期2017-03 启动
  3. Hyperthermic Intraperitoneal Chemotherapy for Advanced Gastric Cancer With Peritoneal Metastatis状态不明NCT03604614牵头方II期2017-06 启动
  4. Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric Cancer状态不明NCT02969148牵头方不分期2016-11 启动
  5. Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection状态不明NCT02711033牵头方II期2015-10 启动
  6. Acupuncture Combined With Chemotherapy for Gastric Cancer After Surgery即将招募NCT07098949研究中心不分期2025-08 启动
  7. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  8. Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios已完成NCT06848400研究中心不分期2025-04 启动
  9. Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial状态不明NCT04744649研究中心II期2021-03 启动
  10. Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant Chemotherapy已完成NCT04360577研究中心不分期2020-05 启动
  11. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  12. Effect of Acupuncture for QoL in Gastric Cancer Patients Undergoing Adjuvant Chemotherapy: a Pilot Study已完成NCT03753399研究中心不分期2019-01 启动
  13. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986研究中心II期2016-09 启动
  14. Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.已撤回NCT02736552研究中心III期2016-03 启动
  15. Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)已完成NCT02745509研究中心不分期2016-03 启动
  16. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2状态不明NCT02356276研究中心III期2015-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肺癌

Lung cancer

2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 41 篇,占 0.2%。

牵头论文
41
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
6
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 6620222023: 7720232024: 7720242025: 11112025

广州有 17 家医院列在肺癌下全国有 251 家医院列在肺癌下

这家医院参与的开放试验 6

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Electro-Acupuncture in Lung cancER : EALER Study
    分期
    不分期
    开始
    2026-01
    发布
    登记号
    NCT07337096

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心广州

  2. 正在招募
    Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
    分期
    不分期
    开始
    2026-03
    发布
    登记号
    NCT07348965

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  3. 正在招募
    Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
    分期
    II期
    开始
    2026-11
    发布
    登记号
    NCT07709585

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  4. 正在招募
    Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
    分期
    不分期
    开始
    2022-06
    发布
    登记号
    NCT05378334

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 1 家列出的医院为研究中心广州

  5. 正在招募
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    分期
    I/II期
    开始
    2021-09
    发布
    登记号
    NCT04930432

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛

  6. 即将招募
    A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
    分期
    未注明
    开始
    2026-01
    发布
    登记号
    NCT07338396

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、广州、成都

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室肿瘤内科临床试验/研究机构病理/检验科影像/核医学科

这些论文过半是实验室或动物研究。

牵头的论文41
  1. Exploring the mechanisms of Hu-gu-xiao-ji formula and its components for treatment on non-small cell lung cancer using UPLC-QTOF-MS/MS, network pharmacology, and experiments.2026Journal of ethnopharmacology
  2. Fuzheng Kang'ai Formula suppresses NSCLC by inducing a functional crosstalk between autophagy and ferroptosis via EZH2/DOT1L/H3K79me2 signaling.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Ginsenoside F3 alleviates T cell exhaustion via RIPOR2-mediated immunometabolic reprogramming to potentiate anti-PD-1 therapy.2026Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. Design, synthesis, and biological evaluation of Osimertinib-Cy7 (OSA-Cy7) conjugate as potential theranostic agent targeting activating EGFR mutations.2025BMC biotechnology免费全文
  5. Bevacizumab-associated glomerular microangiopathy: a case report and literature review.2025BMC nephrology免费全文
  6. Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses.2025BMJ open免费全文
  7. Polyphyllin I induces ferritinophagy dependent ferroptosis through EZH2 and promotes anti-tumor immunity.2025Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. Regulation of cisplatin resistance in lung cancer by epigenetic mechanisms.2025Clinical epigenetics免费全文
  9. Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports.2025Frontiers in immunology免费全文
  10. Serum taurine affects lung cancer progression by regulating tumor immune escape mediated by the immune microenvironment.2025Journal of advanced research免费全文
  11. Xiaoji decoction induces apoptosis in lung cancer cells and M1 Macrophage polarization via the JAK1/STAT3/PD-L1 pathway.2025Journal of ethnopharmacology
  12. Berberine restrains non-small cell lung cancer cell growth, invasion and glycolysis via inactivating the SPC25/NUF2 pathway.2025Naunyn-Schmiedeberg's archives of pharmacology
  13. Hu-gu-xiao-ji formula reprograms macrophage polarization and suppresses tumor growth to improve non-small cell lung cancer with bone metastasis via multiple signaling pathways.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  14. Acupuncture reduced incidence of insomnia symptoms in patients with lung cancer: a retrospective cohort study.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer免费全文
  15. Unraveling impact and potential mechanisms of baseline pain on efficacy of immunotherapy in lung cancer patients: a retrospective and bioinformatic analysis.2024Frontiers in immunology免费全文
  16. Complete Response of Locally Advanced Lung Adenocarcinoma Following Basil Combined With Cisplatin Plus Pemetrexed Chemotherapy: A Case Report.2024Integrative cancer therapies免费全文
  17. Efficacy and Safety of Huachansu as an Adjuvant Therapy for Non-Small Cell Lung Cancer: An Overview of Systematic Reviews and Meta-Analyses.2024Integrative cancer therapies
  18. Integrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites.2024International journal of biological macromolecules
  19. Exploring the Mechanism of Ferroptosis Induction by Sappanone A in Cancer: Insights into the Mitochondrial Dysfunction Mediated by NRF2/xCT/GPX4 Axis.2024International journal of biological sciences免费全文
  20. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.2024Journal of ethnopharmacology
  21. Xie-Bai-San increases NSCLC cells sensitivity to gefitinib by inhibiting Beclin-1 mediated autophagosome formation.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  22. BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.2023BMC cancer免费全文
  23. SOX2-associated signaling pathways regulate biological phenotypes of cancers.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  24. Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer.2023Carcinogenesis
  25. The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review.2023International immunopharmacology
  26. Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.2023Nature communications免费全文
  27. Kaempferol promotes non-small cell lung cancer cell autophagy via restricting Met pathway.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  28. Sinomenine hydrochloride bidirectionally inhibits progression of tumor and autoimmune diseases by regulating AMPK pathway.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  29. Lung cancer organoids, a promising model still with long way to go.2022Critical reviews in oncology/hematology
  30. Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.2022Experimental biology and medicine (Maywood, N.J.)免费全文
  31. Renal Metastasis from Squamous Cell Carcinoma of the Lung.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  32. Fuzheng Kang' ai decoction inhibits cell proliferation, migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  33. Bone metastasis attenuates efficacy of immune checkpoint inhibitors and displays "cold" immune characteristics in Non-small cell lung cancer.2022Lung cancer (Amsterdam, Netherlands)
  34. Down-regulating Nrf2 by tangeretin reverses multiple drug resistance to both chemotherapy and EGFR tyrosine kinase inhibitors in lung cancer.2022Pharmacological research
  35. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.2021BMC cancer免费全文
  36. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.2021Cancer medicine免费全文
  37. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.2021Clinical lung cancer
  38. Periodontal disease and the risk of prostate cancer: a meta-analysis of cohort studies.2021International braz j urol : official journal of the Brazilian Society of Urology免费全文
  39. Combined Metabolomics with Transcriptomics Reveals Important Serum Biomarkers Correlated with Lung Cancer Proliferation through a Calcium Signaling Pathway.2021Journal of proteome research
  40. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.2021Journal of the National Comprehensive Cancer Network : JNCCN
  41. Apoptotic activities of brusatol in human non-small cell lung cancer cells: Involvement of ROS-mediated mitochondrial-dependent pathway and inhibition of Nrf2-mediated antioxidant response.2021Toxicology
中文论文(未计入)1
  1. [Solasonine promotes apoptosis of non-small cell lung cancer cells by regulating the Bcl-2/Bax/caspase-3 pathway].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
  1. Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC状态不明NCT05027100牵头方(推断)不分期2021-09 启动
  2. Electro-Acupuncture in Lung cancER : EALER Study正在招募NCT07337096研究中心不分期2026-01 启动
  3. A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients即将招募NCT07338396研究中心2026-01 启动
  4. Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis正在招募NCT07348965研究中心不分期2026-03 启动
  5. Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients正在招募NCT07709585研究中心II期2026-11 启动
  6. Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients正在招募NCT05378334研究中心不分期2022-06 启动
  7. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors正在招募NCT04930432研究中心I/II期2021-09 启动
  8. Acupuncture for Enhancing Immunotherapy in Advanced NSCLC:a Pilot Study进行中,不再招募NCT06461338研究中心不分期2024-08 启动
  9. Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI状态不明NCT06277674研究中心II期2023-11 启动
  10. Tumor Growth Rate (TGR) Predicts Clinical Outcomes for Advanced Non-small Cell Lung Cancer Undergoing Immunotherapy.状态不明NCT04722406研究中心2019-08 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胰腺癌

Pancreatic cancer

2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.1%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 1120232024: 2220242025: 112025

广州有 13 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胰腺癌开放试验。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

打开 PubMed 检索ClinicalTrials.gov

癌症

乳腺癌

Breast cancer

2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 50 篇,占 0.3%。

牵头论文
50
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 3320222023: 111120232024: 101020242025: 17172025

广州有 17 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 邀请入组
    Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
    分期
    不分期
    开始
    2026-01
    发布
    登记号
    NCT07352137

    年龄 18 岁 至 70 岁;仅女性(登记的条件)

    牵头:广东省中医院广州

  2. 正在招募
    Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
    分期
    未注明
    开始
    2022-10
    发布
    登记号
    NCT06551220

    年龄 18 岁 至 80 岁;仅女性(登记的条件)

    牵头方不是列出的医院;另有 15 家列出的医院为研究中心上海、佛山、南京、广州、杭州、汕头、深圳、珠海、福州、衡阳、长沙

  3. 正在招募
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    分期
    IV期
    开始
    2021-06
    发布
    登记号
    NCT04790305

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属肿瘤医院;另有 26 家列出的医院为研究中心上海、北京、南京、合肥、宁波、广州、扬州、武汉、沈阳、济南、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科肿瘤内科临床试验/研究机构病理/检验科
牵头的论文50
  1. Effect of HER2-Low Expression on the Efficacy of CDK4/6 Inhibitors in Breast Cancer: A Meta-Analysis.2026Clinical breast cancer
  2. Target validation and drug discovery for TNBC: Targeting the Lin28B/Let-7/PBK with the ponicidin.2026European journal of medicinal chemistry
  3. Xiaoyao San reverses the pro-breast cancer effect of depression by inhibiting glutamate levels in intestinal flora.2026Journal of ethnopharmacology
  4. Ultrasound-Based Deep Learning Radiomics Nomogram for Tumor and Axillary Lymph Node Status Prediction After Neoadjuvant Chemotherapy.2025Academic radiology
  5. The risk of dementia in breast cancer survivors: a meta-analysis of observational studies.2025Annals of medicine免费全文
  6. Prediction of intraductal cancer microinfiltration based on the hierarchical fusion of peri-tumor imaging histology and dual view deep learning.2025BMC cancer免费全文
  7. Machine learning algorithms predict breast cancer incidence risk: a data-driven retrospective study based on biochemical biomarkers.2025BMC cancer免费全文
  8. Molecular mechanisms of bone metastasis in breast cancer based on transcriptomic and microbiomic analysis.2025Cancer causes & control : CCC免费全文
  9. Clinical Relationship Between Serum ApoB, HER2, and Myocardial Ischemia Risk in Breast Cancer Patients.2025Cancer reports (Hoboken, N.J.)免费全文
  10. Role of low-density cholesterol and Interleukin-17 interaction in breast cancer pathogenesis and treatment.2025Cell biology international
  11. Small protein ERSP encoded by LINC02870 promotes triple negative breast cancer progression via IRE1α/XBP1s activation.2025Cell death and differentiation免费全文
  12. Effect of Huaier granule on prognosis of breast cancer: A single-center propensity score matching retrospective study.2025Chinese medical journal免费全文
  13. Extra-skeletal Ewing's sarcoma with EWSR1::ERG translocation of the breast: a case report.2025Diagnostic pathology免费全文
  14. Ultrasound-based radiomic nomogram for predicting the invasive status of breast cancer: a multicenter study.2025European journal of medical research免费全文
  15. BTG2-deficient mast cells remodel the tumor and tumor-draining lymph node microenvironment leading to chemotherapy resistance in breast cancer.2025Frontiers in immunology免费全文
  16. Atractylodes macrocephala Koidz. Polysaccharide Alleviates Chemotherapy-Induced Depression-Like Behaviors Through the Gut-Brain Axis.2025International journal of molecular sciences免费全文
  17. Liquiritin in Aiduqing formula inhibits breast cancer neoangiogenesis by suppressing CTSK-mediated lysosomal degradation of CXCL1 in tumor-associated macrophages.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  18. The chemosensitizing activity of betulinic acid in suppressing macrophage polarization through GSK-3β/β-catenin/CXCL1 signaling in breast cancer.2025Phytomedicine : international journal of phytotherapy and phytopharmacology
  19. Predicting the axillary lymph node tumor burden in breast cancer patients using ultrasonic radiomics nomogram model.2025PloS one免费全文
  20. Intraoperative ultrasound-guided wire(IOUS-wire) localization biopsy versus preoperative fine needle aspiration cytology(FNAC) for early breast cancer with clinically positive nodes, a retrospective cohort study.2025World journal of surgical oncology免费全文
  21. Clinical and radiological evaluation of a phyllodes tumor of the breast: a case report.2024Anti-cancer drugs
  22. Tanshinone I improves TNBC chemosensitivity by suppressing late-phase autophagy through AKT/p38 MAPK signaling pathway.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  23. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer.2024British journal of cancer免费全文
  24. Tumor-associated macrophages/C-X-C motif chemokine ligand 1 promotes breast cancer autophagy-mediated chemoresistance via IGF1R/STAT3/HMGB1 signaling.2024Cell death & disease免费全文
  25. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.2024Journal of experimental & clinical cancer research : CR免费全文
  26. Baohuoside I chemosensitises breast cancer to paclitaxel by suppressing extracellular vesicle/CXCL1 signal released from apoptotic cells.2024Journal of extracellular vesicles免费全文
  27. Developing liver-targeted naringenin nanoparticles for breast cancer endocrine therapy by promoting estrogen metabolism.2024Journal of nanobiotechnology免费全文
  28. Female patients with hepatitis B may exhibit a reduced risk of breast cancer: A review of NHANES data.2024Medicine免费全文
  29. XIAOPI formula inhibits chemoresistance and metastasis of triple-negative breast cancer by suppressing extracellular vesicle/CXCL1-induced TAM/PD-L1 signaling.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  30. The mediating effect of perceived social support between family resilience and meaning in life in breast cancer patients.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  31. ASO Author Reflections: A More Effective Radiotherapy Modality for Early Breast Cancer: Intraoperative Radiotherapy as a Tumour Bed Boost Combined with Whole Breast Irradiation.2023Annals of surgical oncology
  32. Intraoperative Radiotherapy as a Tumour-Bed Boost Combined with Whole Breast Irradiation Versus Conventional Radiotherapy in Patients with Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.2023Annals of surgical oncology免费全文
  33. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  34. Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway.2023Cancer letters
  35. Cefoselis enhances breast cancer chemosensitivity by directly targeting GRP78/LRP5 signalling of cancer stem cells.2023Clinical and translational medicine免费全文
  36. 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling.2023Drug design, development and therapy免费全文
  37. A Delphi Study of Expert Consensus on Chinese Medicine Syndrome Differentiation and Herbal Use for Early Breast Cancer.2023Integrative cancer therapies免费全文
  38. Naringenin in Si-Ni-San formula inhibits chronic psychological stress-induced breast cancer growth and metastasis by modulating estrogen metabolism through FXR/EST pathway.2023Journal of advanced research免费全文
  39. An Unsupervised Learning-Based Regional Deformable Model for Automated Multi-Organ Contour Propagation.2023Journal of digital imaging免费全文
  40. Chronic psychological stress promotes breast cancer pre-metastatic niche formation by mobilizing splenic MDSCs via TAM/CXCL1 signaling.2023Journal of experimental & clinical cancer research : CR免费全文
  41. A novel incision technique of a totally implanted venous access port in the upper arm for patients with breast cancer.2023World journal of surgical oncology免费全文
  42. Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients.2022Annals of palliative medicine
  43. 1H-NMR based metabolic study of MMTV-PyMT mice along with pathological progress to screen biomarkers for the early diagnosis of breast cancer.2022Molecular omics
  44. Crosstalk between Depression and Breast Cancer via Hepatic Epoxide Metabolism: A Central Comorbidity Mechanism.2022Molecules (Basel, Switzerland)免费全文
  45. Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers.2021Aging免费全文
  46. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.2021Cancer medicine免费全文
  47. Aiduqing formula inhibits breast cancer metastasis by suppressing TAM/CXCL1-induced Treg differentiation and infiltration.2021Cell communication and signaling : CCS免费全文
  48. Chinese Medicine Syndromes and Stages of Early Breast Cancer: Hierarchical Cluster Analysis and Implication for Clinical Practice.2021Journal of alternative and complementary medicine (New York, N.Y.)
  49. The Effectiveness of Tai Chi in Patients With Breast Cancer: An Overview of Systematic Reviews and Meta-Analyses.2021Journal of pain and symptom management
  50. Aiduqing formula suppresses breast cancer metastasis via inhibiting CXCL1-mediated autophagy.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
中文论文(未计入)2
  1. [Kaixinsan alleviates adriamycin-induced depression-like behaviors in mice by reducing ferroptosis in the prefrontal cortex].2024Nan fang yi ke da xue xue bao = Journal of Southern Medical University免费全文
  2. [Mechanism of Kaixin Powder in alleviating breast cancer chemotherapy-induced cognitive impairment by transcriptome association analysis].2024Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Endoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision邀请入组NCT07352137牵头方不分期2026-01 启动
  2. Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns正在招募NCT06551220研究中心2022-10 启动
  3. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer正在招募NCT04790305研究中心IV期2021-06 启动
  4. Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China状态不明NCT04076111研究中心2019-09 启动
  5. Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer状态不明NCT01642771研究中心III期2012-06 启动
  6. Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients状态不明NCT01503905研究中心不分期2011-12 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胶质瘤

Glioma

2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.2%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 2220222023: 2220232024: 0020242025: 222025

广州有 13 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的胶质瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科影像/核医学科
牵头的论文12
  1. LRP5 enhances glioma cell proliferation by modulating the MAPK/p53/cdc2 pathway.2025International journal of medical sciences免费全文
  2. MRI-based habitat radiomics for preoperatively predicting IDH status in gliomas.2025Neurosurgical focus
  3. A review of traditional Chinese medicine Curcumae Rhizoma for treatment of glioma.2023International review of neurobiology
  4. An overview of Twist1 in glioma progression and recurrence.2023International review of neurobiology
  5. Radiomic Analysis of Contrast-Enhanced MRI Predicts DNA Copy-Number Subtype and Outcome in Lower-Grade Gliomas.2022Academic radiology
  6. A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma.2022Frontiers in immunology免费全文
  7. Lower-Grade Gliomas: Predicting DNA Methylation Subtyping and its Consequences on Survival with MR Features.2021Academic radiology
  8. Heparanase confers temozolomide resistance by regulation of exosome secretion and circular RNA composition in glioma.2021Cancer science免费全文
  9. Development of MR-based preoperative nomograms predicting DNA copy number subtype in lower grade gliomas with prognostic implication.2021European radiology
  10. Targeted therapy with anlotinib for a leptomeningeal spread recurrent glioblastoma patient.2021Progress in brain research
  11. Multimodal imaging in the differential diagnosis of glioma recurrence from treatment-related effects: A protocol for systematic review and network meta-analysis.2021Progress in brain research
  12. Network pharmacological mechanism of Cinobufotalin against glioma.2021Progress in brain research

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

广州有 30 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

广州有 12 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025

广州有 22 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

广州有 9 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

β 地中海贫血

Beta thalassaemia

2021–2025 年没有牵头β 地中海贫血的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 18 家医院列在β 地中海贫血下全国有 133 家医院列在β 地中海贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的β 地中海贫血开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

视神经脊髓炎谱系疾病

Neuromyelitis optica spectrum disorder

2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 222025

广州有 9 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。

这些数字背后的记录
研究主题抗体与诊断急性发作治疗生物制剂
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 7 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis进行中,不再招募NCT06298552研究中心III期2024-04 启动
  2. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis进行中,不再招募NCT06558279研究中心III期2024-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

冠心病

Coronary heart disease

2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.3%。

牵头论文
15
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 4420222023: 3320232024: 2220242025: 332025

广州有 10 家医院列在冠心病下全国有 231 家医院列在冠心病下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
    分期
    不分期
    开始
    2026-09
    发布
    登记号
    NCT07803471

    年龄 40 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 2 家列出的医院为研究中心广州、郑州

  2. 即将招募
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    分期
    不分期
    开始
    2021-09
    发布
    登记号
    NCT04995159

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室儿科
牵头的论文15
  1. Causal association between lipoproteins and risk of coronary artery disease-a systematic review and meta-analysis of Mendelian randomization studies.2026Clinical research in cardiology : official journal of the German Cardiac Society
  2. Causality between Cholecystectomy, Blood Lipids, and Major Adverse Cardiac and Cerebrovascular Events: A Multimodal Approach Highlighting Lipid Regulation.2025Bulletin of experimental biology and medicine
  3. Comprehensive Analysis Based on Genes Associated With Cuproptosis, Ferroptosis, and Pyroptosis for the Prediction of Diagnosis and Therapies in Coronary Artery Disease.2025Cardiovascular therapeutics免费全文
  4. Causal effects between gut microbiota and coronary heart disease: A Mendelian randomization study.2025Medicine免费全文
  5. Giant right coronary artery aneurysm with right coronary artery-right atrial fistula.2024Coronary artery disease
  6. Integrating Network Pharmacology and Experimental Validation to Investigate the Mechanism of Qushi Huatan Decoction Against Coronary Heart Disease.2024Drug design, development and therapy免费全文
  7. Development and Validation of Prediction Models for All-Cause Mortality and Cardiovascular Mortality in Patients on Hemodialysis: A Retrospective Cohort Study in China.2023Clinical interventions in aging免费全文
  8. Cardiovascular involvement in Epstein-Barr virus infection.2023Frontiers in immunology免费全文
  9. Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis.2023Journal of interventional cardiology免费全文
  10. Ferritinophagy in vascular endothelial cells regulated by nanoparticles may benefit the prevention of atherosclerosis and in-stent restenosis.2022Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  11. Correlation between Characteristics of Coronary Plaque and Chinese Medicine Syndromes of Coronary Heart Disease: A Cross-Sectional Study Analysed by Intravascular Ultrasound.2022Chinese journal of integrative medicine
  12. CALM1 rs3179089 polymorphism might contribute to coronary artery disease susceptibility in Chinese male: a case-control study.2022Genes & genomics
  13. Application value of Qisexingtai hand diagnostic method in diagnosis of coronary artery disease.2022Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan免费全文
  14. Effect of Tongguan Capsules () on Restenosis after Coronary Stent Implantation: Study Protocol for A Randomized Controlled Trial.2021Chinese journal of integrative medicine
  15. Chemical profile and potential mechanisms of Huo-Tan-Chu-Shi decoction in the treatment of coronary heart disease by UHPLC-Q/TOF-MS in combination with network pharmacology analysis and experimental verification.2021Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
中文论文(未计入)1
  1. [Platelet-to-lymphocyte ratio as a biomarker for predicting coronary artery lesions in Chinese children with Kawasaki disease: a Meta analysis].2023Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
  1. The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients状态不明NCT02850627牵头方IV期2016-07 启动
  2. Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease即将招募NCT07803471研究中心不分期2026-09 启动
  3. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System即将招募NCT04995159研究中心不分期2021-09 启动
  4. Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve Quality状态不明NCT03018769研究中心2016-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性心脏病

Congenital heart disease

2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。

牵头论文
7
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 1120222023: 2220232024: 0020242025: 112025

广州有 12 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下

截至 2026年11月18日,ClinicalTrials.gov 上没有列出这家医院的先天性心脏病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

广州有 12 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies即将招募NCT07858175研究中心2026-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 20 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

广州有 2 家医院列在肺淋巴管平滑肌瘤病下全国有 27 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 1120242025: 112025

广州有 13 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.8%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 3320222023: 1120232024: 0020242025: 112025

广州有 16 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
论文中的科室肾内科
牵头的论文6
  1. Moderate to severe chronic arteriolar lesions is an independent risk factor for adverse renal outcomes in IgA nephropathy.2025PloS one免费全文
  2. Nomogram for the prediction of crescent formation in IgA nephropathy patients: a retrospective study.2023BMC nephrology免费全文
  3. The role of urine IgG in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis.2022International urology and nephrology
  4. Prediction of prognosis in immunoglobulin a nephropathy patients with focal crescent by machine learning.2022PloS one免费全文
  5. Comparison between outcomes of IgA nephropathy with nephrotic-range proteinuria and nephrotic syndrome: do podocytes play a role?2022Renal failure免费全文
  6. Volume of Crescents Affects Prognosis of IgA Nephropathy in Patients without Obvious Chronic Renal Pathology.2021American journal of nephrology
早期论文(2016–2020 年)4
  1. MicroRNA-27a-3p directly targets FosB to regulate cell proliferation, apoptosis, and inflammation responses in immunoglobulin a nephropathy.2020Biochemical and biophysical research communications
  2. Small RNA deep sequencing reveals novel miRNAs in peripheral blood mononuclear cells from patients with IgA nephropathy.2020Molecular medicine reports
  3. Successful treatment of severe Pneumocystis pneumonia in an immunosuppressed patient using caspofungin combined with clindamycin: a case report and literature review.2016BMC pulmonary medicine
  4. Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multi-centre registry study.2016Nephrology (Carlton, Vic.)
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy状态不明NCT02231125研究中心IV期2014-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

广州有 9 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。

这些数字背后的记录
论文中的科室病理/检验科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

广东省中医院

Guangdong Provincial Hospital of Chinese Medicine

广州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR Wikidata
Guangdong Provincial Hospital of Traditional Chinese Medicine; Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine (W.W; Guangdong Provincial Hospital of Traditional Chinese Medicine (GPHTCM); Second Clinical College of Guangzhou University of Chinese Medicine; Guangdong Provincial Hospital of Chinese Medicine (Hainan Hospital); GDHCM; Guangdong Hospital of Traditional Chinese Medicine

提出更正下载数据